Gasporox: Executing its long-term strategy - Redeye

Gasporox’s results closely align with RRe expectations, showing seven quarters of positive EBITDA driven by sales from VialArch, GPX1500, and after-sales services. The company is preparing to launch a new version of VialArch in June and is already securing pre-orders from the pharma and beverage sectors. The upcoming debt maturity might pressure the share, while forthcoming earnings and order announcements could boost it.

Länk till analysen i sin helhet: https://www.redeye.se/research/997201/gasporox-executing-its-long-term-strategy?utm_source=finwire&utm_medium=RSS